Therapeutic use of anti-TF-Antigen antibody

Details Therapeutic use of anti-TF-Antigen antibody Therapeutic use of anti-TF-Antigen antibody

2008-05-20

2008-05-20

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S138100

Reexamination Certificate

active

11190165

ABSTRACT:
The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF-Ag, or for detection of tumors or metastatic foci which express TF-Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF-Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF-Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metatstatic foci or tumors which comprise cancer cells expressing TF-Ag.

REFERENCES:
Gura (1997, Science 278:1041-1042).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
(Roitt et al., Immunology, Third Edition (Mosby, London England) p. 1.7).
Canevari et al. (1994, Annals of Oncology, 1994, 5:698-701).
Harris et al (1993, TIBTECH 11:42-44).
White et al. (2001, Ann. Rev. Med. 52:125-145).
Dermer et al. (Bio/Technology, 1994, 12:320).
Osband et al. (Immunol. Today, 11:193-195, 1990).
Tockman et al (Cancer Res., 1998, (Suppl), 52:2711s-2718).
Busken, C et al, (Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850).
Glinsky, et al., The Role of Thomsen-Friedenreich Antigen in Adhesion of Human Breast and Prostate Cancer Cells to the Endothelium, Cancer Research 61, Jun. 15, 2001, pp. 4851-4857.
Springer, et al., Proposed Molecular Basis of Murine Tumor Cell-Hepatocyte Interaction, The Journal of Biological Chemistry, vol. 258, No. 9, Issue of May 10, 1983, pp. 5702-5706.
Khaldoyanidi, et al., MDA-MB-435 Human Breast Carcinoma Cell Homo- and Heterotypic Adhesion under Flow Conditions Is Mediated in Part by Thomsen-Friedenreich Antigen-Galectin-3 Interactions, The Journal of Biological Chemistry, vol. 278, No. 6, Issue of Feb. 7, 2003, pp. 4127-4134.
Landon, et al., Combinatorial Evolution of High-Affinity Peptides that Bind to the Thomsen-Friedenriech Carcinoma Antigen, Journal of Protein Chemistry, vol. 22, No. 2, Feb. 2003, pp. 193-204.
Rittenhouse-Diakun, et al.; Development and Characterization of Monoclonal Antibody to T-Antigen: (Galbetal-3GalNac-alpha-O); Hybridome, vol. 17, No. 2, 1998; pp. 165-173.
Shigeoka, et al.; Inhibition of liver mestastases from neuraminidase-treated colon 26 cells by an anti-Thomsen-Friedenreich-specific monoclonal antibody; Tumour Biol. 1999, vol. 20, No. 3; 1 page (abstract).
Springer; Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy; J. Mol. Med. 1997, vol. 75; pp. 594-602.

Affiliated with

Also associated with

Rating

Therapeutic use of anti-TF-Antigen antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic use of anti-TF-Antigen antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of anti-TF-Antigen antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3957534